Literature DB >> 31662587

Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules.

Pierre Azoulay1, Danielle Li2, Joshua S Graff Zivin3, Bhaven N Sampat4.   

Abstract

We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly linking specific grant expenditures to private-sector innovations. Second, we take advantage of idiosyncratic rigidities in the rules governing NIH peer review to generate exogenous variation in funding across research areas. Our results show that NIH funding spurs the development of private-sector patents: a $10 million boost in NIH funding leads to a net increase of 2.3 patents. Though valuing patents is difficult, we report a range of estimates for the private value of these patents using different approaches.

Entities:  

Keywords:  NIH; academic research; economics of science; knowledge spillovers; patenting

Year:  2018        PMID: 31662587      PMCID: PMC6818650          DOI: 10.1093/restud/rdy034

Source DB:  PubMed          Journal:  Rev Econ Stud        ISSN: 0034-6527


  25 in total

1.  Evergreening, patent challenges, and effective market life in pharmaceuticals.

Authors:  C Scott Hemphill; Bhaven N Sampat
Journal:  J Health Econ       Date:  2012-02-09       Impact factor: 3.883

2.  Does targeted, disease-specific public research funding influence pharmaceutical innovation?

Authors:  Margaret E Blume-Kohout
Journal:  J Policy Anal Manage       Date:  2012

Review 3.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Wanted: better benchmarks.

Authors:  John H Marburger
Journal:  Science       Date:  2005-05-20       Impact factor: 47.728

5.  Evaluating the federal role in financing health-related research.

Authors:  A M Garber; P M Romer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Intellectual property. Drug patents at the Supreme Court.

Authors:  C Scott Hemphill; Bhaven Sampat
Journal:  Science       Date:  2013-03-22       Impact factor: 47.728

7.  The slowing of treatment discovery, 1965-1995.

Authors:  R J Wurtman; R L Bettiker
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

8.  The Impact of Research Grant Funding on Scientific Productivity.

Authors:  Brian A Jacob; Lars Lefgren
Journal:  J Public Econ       Date:  2011-10-01

9.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.

Authors:  F Fourrier; C Chopin; J Goudemand; S Hendrycx; C Caron; A Rime; A Marey; P Lestavel
Journal:  Chest       Date:  1992-03       Impact factor: 9.410

10.  The value of specialty oncology drugs.

Authors:  Dana P Goldman; Anupam B Jena; Darius N Lakdawalla; Jennifer L Malin; Jesse D Malkin; Eric Sun
Journal:  Health Serv Res       Date:  2009-10-29       Impact factor: 3.402

View more
  6 in total

1.  Administrative Discretion in Scientific Funding: Evidence from a Prestigious Postdoctoral Training Program.

Authors:  Donna K Ginther; Misty L Heggeness
Journal:  Res Policy       Date:  2020-03-14

2.  Early-career setback and future career impact.

Authors:  Yang Wang; Benjamin F Jones; Dashun Wang
Journal:  Nat Commun       Date:  2019-10-01       Impact factor: 14.919

3.  The ripple effects of funding on researchers and output.

Authors:  Reza Sattari; Jung Bae; Enrico Berkes; Bruce A Weinberg
Journal:  Sci Adv       Date:  2022-04-22       Impact factor: 14.957

4.  Scientific rewards for biomedical specialization are large and persistent.

Authors:  Gaétan de Rassenfosse; Kyle Higham; Orion Penner
Journal:  BMC Biol       Date:  2022-09-30       Impact factor: 7.364

Review 5.  Key opinion leaders - a critical perspective.

Authors:  Jose U Scher; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2020-11-30       Impact factor: 32.286

6.  Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity.

Authors:  Sabrina Wimmer; Sarai M Keestra
Journal:  Int J Health Policy Manag       Date:  2022-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.